Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

clinicaltrials.gov/study/NCT00168012

Is a

‌

Clinical study

Clinical Study attributes

NCT Number

NCT001680120

Health Conditions in Trial

‌

Common variable immunodeficiency

IgG deficiency

Trial Recruitment Size

420

Trial Sponsor

CSL Behring

Clinical Trial Start Date

2004

Study Completion Date

2005

Clinical Trial Study Type

Interventional0

Interventional Trial Purpose

Treatment0

Interventional Trial Phase

Phase 30

Official Name

An Open Study to Evaluate the Safety and Efficacy of IVIG-F10 in Patients With Primary Immunodeficiency Diseases (PID)0

Last Updated

February 11, 2011

Allocation Type

Non-Randomized0

Intervention Model

Single Group Assignment0

Masking Type

None (Open Label)0

Study summary

The purpose of this study is to demonstrate the effect of IVIG-F10 on the prevention of serious bacterial infections in patients with primary immunodeficiency. As secondary endpoints the rate of overall infections, the tolerability and safety of IVIG-F10 are studied.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

Contents

Clinical Study attributes

Timeline

Further Resources

References

Find more entities like Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)